Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
Antiviral drugs have gained significant attention in recent years due to the outbreak of various viral diseases. Tanzania, being one of the developing countries in Africa, has witnessed a surge in demand for antiviral drugs.
Customer preferences: The customer preferences in Tanzania are primarily driven by the increasing number of viral diseases. The majority of the population in Tanzania lives in rural areas, and hence, the demand for antiviral drugs is higher in rural areas as compared to urban areas. The affordability of antiviral drugs is also a significant factor that influences customer preferences.
Trends in the market: The antiviral drugs market in Tanzania has witnessed significant growth in recent years. The increasing prevalence of viral diseases, such as HIV/AIDS, Ebola, and Zika, has resulted in a surge in demand for antiviral drugs. The government has also taken several initiatives to improve healthcare services in the country, which has further fueled the growth of the antiviral drugs market. The market is expected to continue its growth trajectory in the coming years due to the increasing awareness about viral diseases and the availability of advanced antiviral drugs.
Local special circumstances: Tanzania faces several challenges in the healthcare sector, such as inadequate infrastructure, shortage of healthcare professionals, and limited access to healthcare facilities in rural areas. These challenges have resulted in a significant burden on the healthcare system, leading to a rise in the prevalence of viral diseases. The government has taken several initiatives to address these challenges, such as increasing the healthcare budget and improving healthcare infrastructure.
Underlying macroeconomic factors: Tanzania is one of the fastest-growing economies in Africa, with a GDP growth rate of around 6% in recent years. The country has witnessed significant economic growth, which has resulted in an increase in disposable income and improved living standards. This has led to an increase in the demand for healthcare services, including antiviral drugs. The government has also taken several measures to promote foreign investment in the country, which has further fueled the growth of the antiviral drugs market. In conclusion, the antiviral drugs market in Tanzania is witnessing significant growth due to increasing customer preferences, rising awareness about viral diseases, and government initiatives to improve healthcare services. The market is expected to continue its growth trajectory in the coming years, driven by the underlying macroeconomic factors and increasing demand for advanced antiviral drugs.
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights